Combining Network Pharmacology and Transcriptomics to Investigate the Mechanisms of Yujiang Paidu Decoction in the Treatment of Chronic Rhinosinusitis with Nasal Polyps

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2024 Sep 2

PMID 39219695

Authors

Yujie Li

Yadong Yin

Juan Xiong

Zhipeng Zhang

Linglong Li

Baoshun Zhang

Feng Zhang

Dehong Mao

Affiliations

Soon will be listed here.

Abstract

Background: Yujiang Paidu Decoction (YJPD) has demonstrated clinical efficacy in the treatment of chronic rhinosinusitis. However, the effects and mechanisms of the YJPD on chronic rhinosinusitis with nasal polyps (CRSwNP) remain unclear.

Purpose: This study aimed to elucidate the potential mechanism of action of YJPD in the treatment of CRSwNP based on network pharmacology, transcriptomics and experiments.

Methods: A CRSwNP mouse model was established using ovalbumin (OVA) and staphylococcus aureus enterotoxin B (SEB) for 12 weeks and the human nasal epithelial cell (HNEpC) model was induced with IL-13 in vitro. Behavioral tests, scanning electron microscopy (SEM), micro-CT and pathological change of nasal tissues were observed to investigate the therapeutic effects of YJPD. Network pharmacology and transcriptomics were launched to explore the pharmacological mechanisms of YJPD in CRSwNP treatment. Finally, an ELISA, immunofluorescence, RT-qPCR, Western blotting and Tunel were performed for validation.

Results: Different doses of YJPD intervention effectively alleviated rubbing and sneezing symptoms in CRSwNP mice. Additionally, YJPD significantly reduced abnormal serological markers, structural damage of the nasal mucosa, inflammatory cell infiltration, goblet cell increases, and inhibited OVA-specific IgE levels and the secretion of Th2 cytokines such as IL-4, IL-5, and IL-13. Moreover, transcriptomics and network pharmacology analyses indicated that YJPD may exert anti-inflammatory and anti-apoptotic effects by inhibiting the MAPK/AP-1 signaling pathway. The experimental findings supported this conclusion, which was further corroborated by similar results observed in IL13-induced HNEpCs in vitro.

Conclusion: YJPD could alleviate inflammatory status and epithelial apoptosis by inhibiting aberrant activation of MAPK/AP-1 signaling pathway. This finding provides a strong basis for using YJPD as a potential treatment in CRSwNP.

References

Zhao Y, Woo K, Ma K, van Hansselt C, Wong K, Cheng K . Treatment of perennial allergic rhinitis using Shi-Bi-Lin, a Chinese herbal formula. J Ethnopharmacol. 2009; 122(1):100-5. DOI: 10.1016/j.jep.2008.12.005. View

Ordovas-Montanes J, Dwyer D, Nyquist S, Buchheit K, Vukovic M, Deb C . Allergic inflammatory memory in human respiratory epithelial progenitor cells. Nature. 2018; 560(7720):649-654. PMC: 6133715. DOI: 10.1038/s41586-018-0449-8. View

Shingnaisui K, Dey T, Manna P, Kalita J . Therapeutic potentials of Houttuynia cordata Thunb. against inflammation and oxidative stress: A review. J Ethnopharmacol. 2018; 220:35-43. PMC: 7127360. DOI: 10.1016/j.jep.2018.03.038. View

Spiegelberg H . The role of interleukin-4 in IgE and IgG subclass formation. Springer Semin Immunopathol. 1990; 12(4):365-83. DOI: 10.1007/BF00225324. View

Yap L, Pothula V, Warner J, Akhtar S, Yates E . The root and development of otorhinolaryngology in traditional Chinese medicine. Eur Arch Otorhinolaryngol. 2009; 266(9):1353-9. DOI: 10.1007/s00405-009-1041-5. View

Gandhi N, Bennett B, Graham N, Pirozzi G, Stahl N, Yancopoulos G . Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2015; 15(1):35-50. DOI: 10.1038/nrd4624. View

Bachert C, Han J, Desrosiers M, Hellings P, Amin N, Lee S . Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019; 394(10209):1638-1650. DOI: 10.1016/S0140-6736(19)31881-1. View

Ran X, Ma L, Peng C, Zhang H, Qin L . Ligusticum chuanxiong Hort: a review of chemistry and pharmacology. Pharm Biol. 2011; 49(11):1180-9. DOI: 10.3109/13880209.2011.576346. View

Gong L, Zou W, Zheng K, Shi B, Liu M . The Herba Patriniae (Caprifoliaceae): A review on traditional uses, phytochemistry, pharmacology and quality control. J Ethnopharmacol. 2020; 265:113264. PMC: 7443212. DOI: 10.1016/j.jep.2020.113264. View

10.

Khorasanizadeh M, Eskian M, Gelfand E, Rezaei N . Mitogen-activated protein kinases as therapeutic targets for asthma. Pharmacol Ther. 2017; 174:112-126. DOI: 10.1016/j.pharmthera.2017.02.024. View

11.

Zhou L, Xue C, Chen Z, Jiang W, He S, Zhang X . c-Fos is a mechanosensor that regulates inflammatory responses and lung barrier dysfunction during ventilator-induced acute lung injury. BMC Pulm Med. 2022; 22(1):9. PMC: 8734268. DOI: 10.1186/s12890-021-01801-2. View

12.

Dunston D, Ashby S, Krosnowski K, Ogura T, Lin W . An effective manual deboning method to prepare intact mouse nasal tissue with preserved anatomical organization. J Vis Exp. 2013; (78). PMC: 3854956. DOI: 10.3791/50538. View

13.

Joo Y, Cho H, Jeon Y, Kim J, Jung M, Jeon S . Therapeutic Effects of Intranasal Tofacitinib on Chronic Rhinosinusitis with Nasal Polyps in Mice. Laryngoscope. 2020; 131(5):E1400-E1407. DOI: 10.1002/lary.29129. View

14.

Santini G, Mores N, Malerba M, Mondino C, Anzivino R, Macis G . Dupilumab for the treatment of asthma. Expert Opin Investig Drugs. 2017; 26(3):357-366. DOI: 10.1080/13543784.2017.1282458. View

15.

Sugiura R, Satoh R, Takasaki T . ERK: A Double-Edged Sword in Cancer. ERK-Dependent Apoptosis as a Potential Therapeutic Strategy for Cancer. Cells. 2021; 10(10). PMC: 8533760. DOI: 10.3390/cells10102509. View

16.

Zhang Y, Song Y, Wang C, Jiang J, Liu S, Bai Q . Panax notoginseng saponin R1 attenuates allergic rhinitis through AMPK/Drp1 mediated mitochondrial fission. Biochem Pharmacol. 2022; 202:115106. DOI: 10.1016/j.bcp.2022.115106. View

17.

Zhang Y, Gevaert E, Lou H, Wang X, Zhang L, Bachert C . Chronic rhinosinusitis in Asia. J Allergy Clin Immunol. 2017; 140(5):1230-1239. DOI: 10.1016/j.jaci.2017.09.009. View

18.

Haddad E, Cyr S, Arima K, McDonald R, Levit N, Nestle F . Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis. Dermatol Ther (Heidelb). 2022; 12(7):1501-1533. PMC: 9276864. DOI: 10.1007/s13555-022-00737-7. View

19.

Fokkens W, Lund V, Hopkins C, Hellings P, Kern R, Reitsma S . European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020; 58(Suppl S29):1-464. DOI: 10.4193/Rhin20.600. View

20.

Tomassen P, Vandeplas G, Van Zele T, Cardell L, Arebro J, Olze H . Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016; 137(5):1449-1456.e4. DOI: 10.1016/j.jaci.2015.12.1324. View